Avita Medical shares are trading higher after the company announced FDA approval of RECELL for the treatment of full-thickness skin defects.
Portfolio Pulse from Benzinga Newsdesk
Avita Medical announced FDA approval of RECELL for the treatment of full-thickness skin defects, leading to a rise in the company's shares.
June 08, 2023 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avita Medical's shares are trading higher after FDA approval of RECELL for full-thickness skin defects treatment.
The FDA approval of RECELL for the treatment of full-thickness skin defects is a significant milestone for Avita Medical. This approval will likely lead to increased sales and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100